Search

Your search keyword '"Centre de néphrologie et transplantation rénale [Hôpital de la Conception - APHM]"' showing total 2 results
Start Over Author "Centre de néphrologie et transplantation rénale [Hôpital de la Conception - APHM]" Journal transplantation
2 results on '"Centre de néphrologie et transplantation rénale [Hôpital de la Conception - APHM]"'

1. Immunosuppression and Graft Rejection in Living-related HLA-identical Renal Transplantation: The RADOVFULL Study

Author

Ossman, Rim, Jamme, Matthieu, Moulin, Bruno, Legendre, Christophe, Morelon, Emmanuel, Frimat, Luc, Hourmant, Maryvonne, Durrbach, Antoine, Malvezzi, Paolo, Rostaing, Lionel, Luc Taupin, Jean, Mesnard, Laurent, Rondeau, Eric, BRUNET, Philippe, CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Les Hôpitaux Universitaires de Strasbourg (HUS), Unité de Parasitologie-Mycologie, Service de Microbiologie [Hôpital Necker-Enfants-Malades, Paris], Assistance Publique - Hôpitaux de Paris, Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre hospitalier universitaire de Nantes (CHU Nantes), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Centre Hospitalier Universitaire [Grenoble] (CHU), CHU Toulouse [Toulouse], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris 1 Panthéon-Sorbonne - Formation continue Panthéon Sorbonne (UP1 FCPS), Université Paris 1 Panthéon-Sorbonne (UP1), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre de néphrologie et transplantation rénale [Hôpital de la Conception - APHM], Hôpital de la Conception [CHU - APHM] (LA CONCEPTION)-Assistance Publique - Hôpitaux de Marseille (APHM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), and Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION)

Subjects
Graft Rejection, Male, [SDV]Life Sciences [q-bio], Biopsy, medicine.medical_treatment, MISMATCH, 030230 surgery, Kidney, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, 0302 clinical medicine, HLA Antigens, Living Donors, Medicine, 2. Zero hunger, COMPLICATIONS, Histocompatibility Testing, Incidence, Graft Survival, Immunosuppression, Middle Aged, Allografts, 3. Good health, Treatment Outcome, Cohort, Female, 030211 gastroenterology & hepatology, Adult, medicine.medical_specialty, KIDNEY-TRANSPLANTATION, medicine.drug_class, Calcineurin Inhibitors, Urology, Human leukocyte antigen, DONOR, Monoclonal antibody, Young Adult, 03 medical and health sciences, Humans, Family, Retrospective Studies, Immunosuppression Therapy, Transplantation, Dose-Response Relationship, Drug, business.industry, Odds ratio, Kidney Transplantation, Survival Analysis, BODY-MASS INDEX, Calcineurin, RECIPIENTS, Transplantation, Haploidentical, Kidney Failure, Chronic, business, Body mass index, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Follow-Up Studies
Abstract

International audience; Background.We aimed to describe the immunosuppressive regimens and graft rejection rates in living-related HLA-identical (LR HLAid) renal transplantation.Methods.We performed a retrospective multicenter analysis of the French national database for LR HLAid renal transplantations performed between 2002 and 2012. Univariate and multivariate analysis were performed to determine risk factors for graft rejection in LR HLAid recipients.Results.A total of 27 218 renal transplantations were performed, of whom 163 had a LR HLAid donor. About immunosuppressive treatment

Published
2020
Full Text
View/download PDF

2. Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC.

Author

de Fontbrune FS, Galambrun C, Sirvent A, Huynh A, Faguer S, Nguyen S, Bay JO, Neven B, Moussi J, Simon L, Xhaard A, Resche-Riggon M, O'Meara A, Fremeaux-Bacchi V, Veyradier A, Socié G, Coppo P, and de Latour RP

Subjects
Adolescent, Adult, Aged, Child, Child, Preschool, Female, France, Graft vs Host Disease etiology, Graft vs Host Disease mortality, Hematopoietic Stem Cell Transplantation mortality, Humans, Male, Middle Aged, Retrospective Studies, Risk Factors, Severity of Illness Index, Survival Analysis, Thrombotic Microangiopathies diagnosis, Thrombotic Microangiopathies etiology, Thrombotic Microangiopathies mortality, Time Factors, Transplantation, Homologous, Treatment Outcome, Young Adult, Antibodies, Monoclonal, Humanized therapeutic use, Hematopoietic Stem Cell Transplantation adverse effects, Thrombotic Microangiopathies drug therapy
Abstract

Background: Thrombotic microangiopathy (TMA) occurring after allogeneic hematopoietic stem cell transplantation (HSCT) has a devastating prognosis. Response rates to current therapies (mainly plasma exchange) are unsatisfactory. Thrombotic microangiopathy after allogeneic HSCT shares similarities with atypical hemolytic uremic syndrome (aHUS) in the underlying pathomechanisms. Eculizumab has been associated with impressive results in aHUS., Materials and Methods: We retrospectively analyzed 12 patients who received Eculizumab in France between 2010 and 2013 for severe post-HSCT TMA., Results: All 12 patients had severe TMA with neurological and/or renal involvement. Fifty-eight percent were refractory to first-line plasma exchange. At the time of TMA diagnosis, infections were present in 50% of the patients and acute graft-versus-host disease in 33%. Patients were treated with Eculizumab according to the aHUS therapeutic scheme. With a median follow-up of 14 months, hematological response and overall survival were 50% and 33%, respectively. Active acute graft-versus-host disease at TMA diagnosis was the only factor associated with worse overall survival (P = 0.009)., Discussion: Response rate and overall survival after Eculizumab in our cohort compare favorably with previously published data in TMA after allogeneic HSCT. Prospective trials are warranted to confirm these results. Early initiation of Eculizumab may have a favorable effect on long-term renal function and further contribute to the prolongation of survival.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results